{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:56:40Z","timestamp":1781643400279,"version":"3.54.5"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e0 degli Studi di Modena e Reggio Emilia"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    We investigated treatment outcomes, relapse risk, and survival in 104 consecutive patients with non-endemic Burkitt lymphoma (BL) diagnosed and treated in Kazakhstan between 2013 and 2024 in a real-world setting. This was a retrospective, clinically based study analyzing baseline characteristics, treatment regimens, response to first-line therapy, prognostic factors, relapse, and survival. The median age was 26 years (range 2\u201380), with a male predominance (64%). All cases underwent MYC rearrangement assessment, and EBV status was available in 80 patients, with 28% testing positive. Curative-intent therapy was delivered to 95 patients (91%), including R-BFM (44%), R-EPOCH (23%), R-CODOX-M\/R-IVAC (18%), and R-Hyper-CVAD (15%); no patient underwent autologous stem cell transplantation. After a median follow-up of 57 months, the 3-year overall survival (OS) and progression-free survival (PFS) were 57% and 56%, respectively. Patients younger than 18 years, all treated with R-BFM, had significantly superior outcomes compared with adults, with 3-year OS and PFS of 82% and 83%, respectively (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001). Among adults, patients treated with R-Hyper-CVAD or R-CODOX-M\/R-IVAC had better OS than those treated with R-EPOCH (50% vs. 19%,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.04). In univariate analysis, age\u2009\u2265\u200940 years, female sex, ECOG performance status\u2009\u2265\u20092, and platelet count\u2009&lt;\u2009150\u00a0g\/dL were associated with inferior prognosis. In multivariate analysis, age\u2009\u2265\u200940 years remained the only independent adverse prognostic factor. The adapted Burkitt Lymphoma International Prognostic Index retained prognostic value. In conclusion, this large real-world study demonstrates excellent outcomes in pediatric patients treated with intensive immunochemotherapy but substantially inferior results in adults, particularly in refractory disease, highlighting a critical unmet clinical need in this population.\n                  <\/jats:p>","DOI":"10.1007\/s00277-026-06941-1","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:27:03Z","timestamp":1773880023000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Treatment of Burkitt lymphoma in real-world setting: findings on 104 consecutive cases diagnosed and treated in Kazakhstan over the last decade"],"prefix":"10.1007","volume":"105","author":[{"given":"Akmaral","family":"Jazyltayeva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazarii","family":"Shokun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayazhan","family":"Umutbayeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luana","family":"Conte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raigul","family":"Ramazanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vadim","family":"Kemaikin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azat","family":"Karabekov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aidana","family":"Shalabay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aigerim","family":"Koshkarbayeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nurbergen","family":"Kemelbekov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madina","family":"Zhumabay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fariza","family":"Shokubayeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yana","family":"Stepanihyna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Federico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saule","family":"Gabbasova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,19]]},"reference":[{"key":"6941_CR1","doi-asserted-by":"publisher","DOI":"10.1002\/9781119823193.ch44","author":"M Roschewski","year":"2023","unstructured":"Roschewski M, Wilson WH (2023) Burkitt Lymphoma. Cancer Consult. https:\/\/doi.org\/10.1002\/9781119823193.ch44","journal-title":"Cancer Consult"},{"key":"6941_CR2","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s13244-019-0733-7","volume":"10","author":"K Kalisz","year":"2019","unstructured":"Kalisz K, Alessandrino F, Beck R et al (2019) An update on Burkitt lymphoma: a review of pathogenesis and multimodality imaging assessment of disease presentation, treatment response, and recurrence. Insights Imaging 10:56. https:\/\/doi.org\/10.1186\/s13244-019-0733-7","journal-title":"Insights Imaging"},{"issue":"23","key":"6941_CR3","doi-asserted-by":"publisher","first-page":"e01022","DOI":"10.1128\/JVI.01022-18","volume":"92","author":"X Zheng","year":"2018","unstructured":"Zheng X, Wang J, Wei L, Peng Q, Gao Y, Fu Y, Lu Y, Qin Z, Zhang X, Lu J, Ou C, Li Z, Zhang X, Liu P, Xiong W, Li G, Yan Q, Ma J (2018) Epstein-Barr Virus MicroRNA miR-BART5-3p Inhibits p53 Expression. J Virol 92(23):e01022\u2013e01018 PMID: 30209170; PMCID: PMC6232473. https:\/\/doi.org\/10.1128\/JVI.01022-18","journal-title":"J Virol"},{"issue":"2","key":"6941_CR4","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1097\/pas.0000000000000332","volume":"39","author":"A Satou","year":"2015","unstructured":"Satou A, Asano N, Nakazawa A et al (2015) Epstein-Barr virus (EBV)-positive sporadic Burkitt lymphoma: an age-related lymphoproliferative disorder? Am J Surg Pathol 39(2):227\u2013235. https:\/\/doi.org\/10.1097\/pas.0000000000000332","journal-title":"Am J Surg Pathol"},{"key":"6941_CR5","doi-asserted-by":"publisher","unstructured":"Diakite M, Shaw-Saliba K, Lau CY Malignancy and viral infections in Sub-Saharan Africa: a review. Front Virol. 2023:1103737.; https:\/\/doi.org\/10.3389\/fviro.2023.1103737","DOI":"10.3389\/fviro.2023.1103737"},{"key":"6941_CR6","doi-asserted-by":"publisher","unstructured":"Chen BJ, Chang ST, Weng SF, Huang WT, Chu PY, Hsieh PP et al (2016) EBV-associated Burkitt lymphoma in Taiwan is not age-related. Leukemia Lymphoma. ;57(3):644\u2013653. https:\/\/doi.org\/10.3109\/10428194.2015.1076928. PMID: 26422188; https:\/\/doi.org\/10.3109\/10428194.2015.1076928","DOI":"10.3109\/10428194.2015.1076928"},{"key":"6941_CR7","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.ebiom.2018.12.041","volume":"39","author":"TP Velavan","year":"2019","unstructured":"Velavan TP (2019) Epstein-Barr virus, malaria and endemic Burkitt lymphoma. EBioMedicine 39:13\u201314. https:\/\/doi.org\/10.1016\/j.ebiom.2018.12.041","journal-title":"EBioMedicine"},{"key":"6941_CR8","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/bjh.15262","volume":"181","author":"K Zhu","year":"2017","unstructured":"Zhu K, Song J, Connors et al (2017) Excellent real-world outcomes of adults with burkitt lymphoma treated with codox\u2010m\/ivac plus or minus rituximab. Br J Haematol 181:12. https:\/\/doi.org\/10.1111\/bjh.15262","journal-title":"Br J Haematol"},{"issue":"4","key":"6941_CR9","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1111\/bjh.16425","volume":"189","author":"LH Jakobsen","year":"2020","unstructured":"Jakobsen LH, Ellin F, Smeland KB et al (2020) Minimal relapse risk and early normalization of survival for patients with Burkitt lymphoma treated with intensive immunochemotherapy: an international study of 264 real-world patients. Br J Haematol 189(4):661\u2013671. https:\/\/doi.org\/10.1111\/bjh.16425","journal-title":"Br J Haematol"},{"issue":"3","key":"6941_CR10","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1200\/JCO.1996.14.3.925","volume":"14","author":"I Magrath","year":"1996","unstructured":"Magrath I, Adde M, Shad A et al (1996) Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol 14(3):925\u2013934. https:\/\/doi.org\/10.1200\/JCO.1996.14.3.925","journal-title":"J Clin Oncol"},{"key":"6941_CR11","doi-asserted-by":"publisher","first-page":"639","DOI":"10.24953\/turkjped.2021.04.011","volume":"63","author":"S Vural","year":"2021","unstructured":"Vural S, Gen\u00e7 DB, Kebudi R, Do\u011fan \u00d6, Karaman S (2021) Treatment results of modified BFM protocol in pediatric high-risk Burkitt lymphoma. Turk J Pediatr 63:639\u2013647. https:\/\/doi.org\/10.24953\/turkjped.2021.04.011","journal-title":"Turk J Pediatr"},{"issue":"11","key":"6941_CR12","doi-asserted-by":"publisher","first-page":"3370","DOI":"10.1182\/blood.V97.11.3370","volume":"97","author":"C Patte","year":"2001","unstructured":"Patte C, Auperin A, Michon J et al (2001) The Soci\u00e9t\u00e9 Fran\u00e7aise d\u2019Oncologie P\u00e9diatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia. Blood 97(11):3370\u20133379. https:\/\/doi.org\/10.1182\/blood.V97.11.3370","journal-title":"Blood"},{"issue":"10","key":"6941_CR13","first-page":"3294","volume":"94","author":"A Reiter","year":"1999","unstructured":"Reiter A, Schrappe M, Tiemann M et al (1999) Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: a report of the Berlin\u2013Frankfurt\u2013M\u00fcnster Group Trial NHL-BFM 90. Blood 94(10):3294\u20133306","journal-title":"Blood"},{"issue":"9","key":"6941_CR14","doi-asserted-by":"publisher","first-page":"e31145","DOI":"10.1002\/pbc.31145","volume":"71","author":"H Chapman","year":"2024","unstructured":"Chapman H, Ntemi PS, Gisiri M, Vasudevan L, Kashaigili HJ, Schroeder K (2024) Retrospective analysis of pediatric patients with Burkitt lymphoma treated in Tanzania following the implementation of the 2016 National Treatment Guidelines: Poor outcomes to current standard-of-care therapy. Pediatr Blood Cancer 71(9):e31145. https:\/\/doi.org\/10.1002\/pbc.31145","journal-title":"Pediatr Blood Cancer"},{"issue":"5","key":"6941_CR15","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1111\/bjh.13986","volume":"173","author":"CC Stanley","year":"2016","unstructured":"Stanley CC, Westmoreland KD, Heimlich BJ et al (2016) Outcomes for paediatric Burkitt lymphoma treated with anthracycline-based therapy in Malawi. Br J Haematol 173(5):705\u2013712. https:\/\/doi.org\/10.1111\/bjh.13986","journal-title":"Br J Haematol"},{"key":"6941_CR16","doi-asserted-by":"publisher","unstructured":"Broccoli A, Argnani L, Gugliotta G, Pellegrini C, Casadei B, Bagnato G, Gentilini M, Stefoni V, Zinzani PL (2024) The Treatment of Burkitt Lymphoma With the Berlin-Frankfurt-M\u00fcnster Protocol With Rituximab and Consolidative Autologous Transplantation, The Oncologist, Volume 29, Issue 6, June Pages e789\u2013e795. https:\/\/doi.org\/10.1093\/oncolo\/oyae017","DOI":"10.1093\/oncolo\/oyae017"},{"issue":"7","key":"6941_CR17","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1002\/cncr.21776","volume":"106","author":"DA Thomas","year":"2006","unstructured":"Thomas DA, Faderl S, O\u2019Brien S et al (2006) Chemoimmunotherapy with Hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer 106(7):1569\u20131580. https:\/\/doi.org\/10.1002\/cncr.21776","journal-title":"Cancer"},{"issue":"10","key":"6941_CR18","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1093\/annonc\/mdf353","volume":"19","author":"GM Mead","year":"2008","unstructured":"Mead GM, Sydes MR, Walewski J et al (2008) An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt\u2019s lymphoma: results of United Kingdom Lymphoma Group LY06 study. Ann Oncol 19(10):1764\u20131770. https:\/\/doi.org\/10.1093\/annonc\/mdf353","journal-title":"Ann Oncol"},{"issue":"20","key":"6941_CR19","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1056\/nejmoa1308392","volume":"369","author":"K Dunleavy","year":"2013","unstructured":"Dunleavy K, Pittaluga S, Shovlin M et al (2013) Low-intensity therapy in adults with Burkitt\u2019s lymphoma. N Engl J Med 369(20):1915\u20131925. https:\/\/doi.org\/10.1056\/nejmoa1308392","journal-title":"N Engl J Med"},{"issue":"1","key":"6941_CR20","doi-asserted-by":"publisher","first-page":"e22","DOI":"10.55788\/61e584df","volume":"10","author":"MED Chamuleau","year":"2023","unstructured":"Chamuleau MED, Oosten LEM, Thielen FW et al (2023) DA-EPOCH-R vs CODOX-M\/IVAC in adult Burkitt lymphoma: final results from a randomized multicenter trial. Lancet Haematol 10(1):e22\u2013e33. https:\/\/doi.org\/10.55788\/61e584df","journal-title":"Lancet Haematol"},{"key":"6941_CR21","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2022.2053531","author":"JM Ribera","year":"2022","unstructured":"Ribera JM, Garc\u00eda O, Buend\u00eda-Ure\u00f1a B et al (2022) Validation of the Burkitt Lymphoma International Prognostic Index in patients treated with two prospective chemoimmunotherapy trials in Spain. Leuk Lymphoma. https:\/\/doi.org\/10.1080\/10428194.2022.2053531","journal-title":"Leuk Lymphoma"},{"key":"6941_CR22","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1200\/JCO.20.03288","volume":"39","author":"J Odam","year":"2021","unstructured":"Odam J, Olszewski et al (2021) Burkitt Lymphoma International Prognostic Index. J Clin Oncol 39:1129\u20131138. https:\/\/doi.org\/10.1200\/JCO.20.03288. 10.1200\/JCO.20.03288","journal-title":"J Clin Oncol"},{"key":"6941_CR23","doi-asserted-by":"publisher","unstructured":"Evens AM, DO, MSc FACP Burkitt Lymphoma: An International Prognostic Index. Oncology Times 43(7):p 1,10\u201311, April 5, 2021.; https:\/\/doi.org\/10.1097\/01.cot.0000743544.91253.1c","DOI":"10.1097\/01.cot.0000743544.91253.1c"},{"issue":"2","key":"6941_CR24","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s00277-017-3167-7","volume":"97","author":"LEM Oosten","year":"2018","unstructured":"Oosten LEM, Chamuleau MED, Thielen FW, de Wreede LC, Siemes C, Doorduijn JK et al (2018) Treatment of sporadic Burkitt lymphoma in adults, a retrospective comparison of four treatment regimens. Ann Hematol 97(2):255\u2013266. https:\/\/doi.org\/10.1007\/s00277-017-3167-7PMCID: PMC5754407; PMID: 29209924","journal-title":"Ann Hematol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06941-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-06941-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06941-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:26:31Z","timestamp":1781641591000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-06941-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,19]]},"references-count":24,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["6941"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-06941-1","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,19]]},"assertion":[{"value":"12 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable due to the retrospective nature of the study and the use of de-identified registry data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"189"}}